Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.

Clin Exp Allergy · 2007 · PMC1859973 · PMID 17250692

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a possible trendno p-value reported

3 , and indicate a possible trend for increased infection risk in the omalizumab group after 28 weeks of treatment.

also in 1,410 other papers

failed to reach statistical significanceno p-value reported

Because of the wide CIs for this, our findings are consistent with a possible slightly increased risk of infection, although this failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.